Valuation: Cantargia AB

Market Cap 373M 37.5M 32.99M 31.1M 28.37M 53.06M 3.6B 53.47M 145M 1.83B 141M 138M 5.96B P/E 2026 *
-2.38x
P/E 2027 * -2.35x
Enterprise Value 373M 37.5M 32.99M 31.1M 28.37M 53.06M 3.6B 53.47M 145M 1.83B 141M 138M 5.96B EV / Sales 2026 *
933x
EV / Sales 2027 * 10.4x
Free-Float
97.06%
Yield 2026 *
-
Yield 2027 * -
1 day-0.27%
1 week-4.39%
Current month-17.89%
1 month-21.04%
3 months-26.78%
6 months-62.00%
Current year-64.13%
1 week 1.46
Extreme 1.46
1.59
1 month 1.46
Extreme 1.46
2.03
Current year 1.46
Extreme 1.46
6.59
1 year 1.46
Extreme 1.46
6.59
3 years 1
Extreme 1
6.59
5 years 1
Extreme 1
22.34
10 years 1
Extreme 1
71.8
Manager TitleAgeSince
Chief Executive Officer 60 2025-08-31
Director of Finance/CFO 56 2023-06-14
Chief Tech/Sci/R&D Officer - 2025-10-01
Director TitleAgeSince
Chairman 66 2015-12-31
Director/Board Member 55 2017-12-31
Director/Board Member 66 2020-09-30
Date Insider Type Main position Quantity % Market Cap. Importance
6/22/26 Buy

Chief Technology Officer

18,238 0.0073%
6/22/26 Exercice

Director

-74,997 0.0302%
4/2/26 Free

Chief Technology Officer

80,000 0.0322%
Change 5-day change 1-year change 3-year change Capi.($)
-0.27%-4.39%-43.99%-64.72% 37.76M
-3.30%+1.19%+54.62%+104.15% 74.18B
-0.12%-3.82%+34.21%+74.86% 59.55B
+2.71%-1.96%-13.79%+364.46% 25.84B
+0.81%+0.61%-0.49%-5.14% 24.73B
-1.05%+1.07%+21.45%-10.32% 20.87B
-1.70%-3.35%+146.86%+325.69% 15.32B
+2.15%-0.92%+48.93%+169.79% 14.06B
-0.43%-7.56%-20.10%+775.94% 13.12B
+0.04%-3.97%+20.23%+234.69% 11.85B
Average -0.12%-1.71%+24.79%+196.94% 25.96B
Weighted average by Cap. -0.71%-0.83%+34.98%+160.26%

Financials

2026 *2027 *
Net sales 400K 40.2K 35.36K 33.33K 30.41K 56.87K 3.86M 57.32K 155K 1.96M 151K 148K 6.39M 36.05M 3.62M 3.19M 3M 2.74M 5.13M 348M 5.17M 13.97M 177M 13.6M 13.31M 576M
Net income -159M -15.93M -14.02M -13.21M -12.05M -22.54M -1.53B -22.72M -61.44M -778M -59.83M -58.53M -2.53B -151M -15.13M -13.31M -12.55M -11.45M -21.41M -1.45B -21.57M -58.34M -739M -56.81M -55.57M -2.41B
Net Debt - -
Logo Cantargia AB
Cantargia AB is a Sweden-based company engaged in development of antibody therapeutics for the treatment of leukemia. The Company is engaged in the development of a therapy for the treatment of cancer by targeting a cell-surface receptor on malignant stem cells, through the development of antibody therapeutics for eradication of malignant stem cells. Cantargia AB uses the Interleukin-1 receptor accessory protein (IL1RAP), as the target for development of a novel antibody-based therapy for leukemia.
Employees
22
Date Price Change Volume
26-09-24 SEK 1.501 -0.27% 686,055
26-09-23 SEK 1.505 -1.76% 917,107
26-09-22 SEK 1.532 -1.92% 651,831
26-09-21 SEK 1.562 -0.45% 906,177
26-09-18 SEK 1.569 -0.06% 802,009
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
1.501SEK
Average target price
8.250SEK
Spread / Average Target
+449.63%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. CANTA Stock